Melissa Johnson (@idpharmacist) — Bluesky Profile

1 month ago

Join us next Tues. Feb. 10 at 11am ET for a webinar on practical, evidence-based approaches to fungal diagnostic testing.

Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.

Register: https://bit.ly/3OiX1Ez

4 3 1 0

5 months ago

Plague is a high-consequence infectious disease with epidemic potential.

The latest video in our partnership with @glaucomflecken.bsky.social summarizes new research evaluating ciprofloxacin versus aminoglycoside–ciprofloxacin for bubonic plague in Madagascar. 👉 nej.md/DrG27

40 11 3 5

9 months ago

Development and validation of a cephalosporin allergy clinical decision rule Utilising the previously published and internationally validated tool PEN-FAST, we validated the same criteria with minor modifications for low-risk cephalosporin allergies. The results suggest that a...

Link to the article here:
shorturl.at/yyiA2

#DrugAllergy

0 0 0 0

9 months ago

Are You Ready for It? Assessing Cephalosporin Allergies with the CEPH-FAST Score Podcast Episode · DASON Digest · 05/30/2025 · 25m

🎧 New on the DASON Digest Podcast: I chat with @trubianojason.bsky.social about the CEPH-FAST study & transforming cephalosporin allergy evaluation.

Special thanks to Dr. Trubiano for being our guest!

🎙️ Link: shorturl.at/LndE2

#AntimicrobialStewardship #IDSky #Pharmacy #Cephalosporins

2 0 1 0

9 months ago

Infectious Diseases Pharmacists Day is Thursday! Join the chat here 5/22 12-1PMEST help us celebrate the amazing work ID pharmacists do every day. #IDPharmacistsDay, #SIDPAdvocacy, #PharmacistsLeadingChange @sidpharm.bsky.social @accpinfdprn.bsky.social

20 10 0 3

9 months ago

NIAMRRE day 3, last keynote for #AMR, is Christina Sarubbi on antibiotic allergies

Penicillin allergies may be over-reported in EMR, and that is not benign for patients or AMR

0 1 1 0

10 months ago

Dr. Karen Norris at #NIAMRRE2025 shares promising data from a pan fungal #vaccine that may aid in our fight against common #fungal pathogens

3 0 1 0

10 months ago

Masterful presentation by @germhuntermd.bsky.social at #NIAMRRE2025 demonstrating emerging #fungal threats such as azole resistant Aspergillus that require a #OneHealth approach

4 1 1 0

10 months ago

Excellent session at #NIAMRRE2025 discussing alarming rate of adaptation of #fungi and emerging fungal threats that require a #OneHealth approach. First talk by Dr Steven Harris

1 0 0 0

10 months ago

At #NIAMRRE2025 great talk by Dr. Rachel Whitaker on rethinking #AMR from the evolutionary perspective “We are all islands in a microbial sea” (Woese 1998)

3 0 1 0

10 months ago

2025 NIAMRRE Conference May 13-15, 2025 | Raleigh, North Carolina - With a mix of presentations, panels, facilitated discussions, workshops, and informal gatherings, you will leave this conference with new connections and ac...

At the #NIAMRRE2025 conference today… so interesting to hear all the perspectives of the different people working in the #AMR space- human, animal, plant etc. exchange.niamrre.org/2025niamrrea...

1 0 0 0

11 months ago

Relative contribution of pharmacokinetics and immune signatures to clinical outcomes in patients with HIV-associated cryptococcal meningitis Host immune responses to HIV-associated cryptococcal meningitis are thought to play critical roles in disease outcome, yet their interaction with antifungal drug exposure is poorly understood. This study explored the relative associations between immune biomarkers, antifungal drug exposure, and clinical outcomes in HIV-associated cryptococcal meningitis.MethodsWe analyzed plasma and cerebrospinal fluid (CSF) immune biomarkers from 64 participants recruited from the AMBITION-cm trial on days 1, 7 and 14 of antifungal therapy. We estimated individual-level exposure to amphotericin B, flucytosine and fluconazole using non-parametric pharmacokinetic modelling. Principal component analysis (PCA) and network analysis were used to reduce the dimensionality of the dataset of immune biomarkers. Associations between immune biomarkers, PK parameters, and clinical outcomes of fungal burden, opening lumbar pressure, early fungicidal activity (EFA), and 10-week mortality were evaluated.ResultsAn inflammatory CSF response, characterised by coordination between TNF-α, G-CSF and IL-7 signalling, was linked to low fungal burden, low intracranial pressure, and survival. However, neither the value of specific immune biomarkers nor their change over time strongly predicted EFA or mortality. Exposure to amphotericin B was significantly associated with EFA.ConclusionsOur results suggest that favourable clinical outcomes from HIV-associated cryptococcal meningitis are associated with coordinated inflammatory and cytotoxic responses in the CNS. Plasma immune signatures were less consistent in our dataset. There was a notable lack of dynamism in immune biomarkers over time. In terms of interventions, the most convincing evidence is for optimisation of antifungal drug exposure, which was the dominant predictor of EFA.

🔍 Study on 64 HIV+ cryptococcal meningitis patients found CSF inflammation linked to low fungal burden & survival. Amphotericin B exposure tied to early fungicidal activity (EFA). 📉

#idsky

0 1 0 0

11 months ago

Three new UTI antibiotics active vs. ESBL organisms have been approved by the FDA in the past year alone! Which will make it to market first: pivmecillinam, sulopenem-probenecid, or gepotidacin? #IDsky

8 3 2 1

11 months ago

sorry here it is! authors.elsevier.com/a/1knok3AjoX...

1 0 0 0

11 months ago

🍄🍄Happy to share the link to free full text version of our new article in press: Current Antifungals and the Developing Pipeline with the fantastic @moorewjustin.bsky.social. #IDSky #PharmSky Thank you to the editors @drluiso.bsky.social @alukmd.bsky.social & Dr. Helen Boucher for the opportunity.

11 7 1 0

1 year ago

📌

0 0 0 0